Table 1 Demographics, baseline care status, main surgical procedure that caused the abdominal wound healing impairment and comorbidities at baseline in the PP population
Randomized treatment arms | NPWT | CWT |
|---|---|---|
Study participants in the PP population, No | 157 | 174 |
Age, median (IQR), years* | 64 (19) | 66 (18) |
Sex, No. (%) Male / Female* | 96 (61.1) / 61 (38.9) | 92 (52.9) / 82 (47.1) |
Main surgical procedure that caused the abdominal wound healing impairment, No. of study participants with OPS codes documented at baseline (%) | 157 (100) | 172 (98.9) |
OPS categories, No. (%) | ||
Gastric incision, excision, and resection | 4 (2.6) | 3 (1.7) |
Incision, excision, resection and anastomose of the small and large intestine | 58 (36.9) | 64 (37.2) |
Other operation on the small and large intestine | 24 (15.3) | 23 (13.4) |
Appendix surgery | 10 (6.4) | 10 (5.8) |
Rectal surgery | 11 (7.0) | 15 (8.7) |
Liver surgery | 4 (2.6) | 5 (2.9) |
Gall bladder and bile ducts surgery | 14 (8.9) | 12 (7.0) |
Pancreatic surgery | 6 (3.8) | 9 (5.2) |
Closure of abdominal hernias | 11 (7.0) | 6 (3.5) |
Operations on other abdominal regions | 12 (7.6) | 18 (10.5) |
Incision, excision and closure of blood vessels | 0 (0) | 1 (0.6) |
Application of a shunt and bypass to blood vessels | 0 (0) | 1 (0.6) |
Regional lymphadenectomy (removal of several lymph nodes in a region) as an independent intervention | 0 (0) | 1 (0.6) |
Splenectomy | 1 (0.6) | 0 (0) |
Cystectomy | 1 (0.6) | 0 (0) |
Excision and destruction of prostate tissue | 1 (0.6) | 0 (0) |
Radical prostatovesiculectomy | 0 (0) | 2 (1.2) |
Other incision on skin and subcutaneous tissue | 0 (0) | 2 (1.2) |
Time between the surgical procedure that preceded the abdominal wound healing impairment and onset of the SAWHI (clinical diagnosis) (days), No. Mean (SD) [Min–Max] | 156 9.5 (4.7) [0–27] | 174 9.8 (7.0) [0 – 74] |
Time between the surgical procedure that preceded the abdominal wound healing impairment and initiation of study treatment (days), No. Mean (SD) [Min–Max] | 156 10.0 (4.7) [0–28] | 174 10.4 (7.1) [0–76] |
Study participants with outpatient study start, No. (%)* | 13 (8.3) | 19 (10.9) |
Study participants with study start in hospital, No. (%)* | 144 (91.7) | 155 (89.1) |